Immuneering Corporation Class A Common Stock (IMRX) Stock
NASDAQ · IMRX
4.17
Fundamentals
Market cap
$276.26M
Price / Earnings ratio
-4.9x
Price / Sales ratio
N/A
Price / Book ratio
1.5x
Return on assets
-30.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
NeutralIMRXJuly 15, 2026
Zacks Investment ResearchNeutral
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
IMRX

Zacks Investment Research
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
NeutralIMRXJune 12, 2026
Zacks Investment ResearchNeutral
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
IMRX

Stocktwits
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
NeutralIMRXJune 1, 2026
StocktwitsNeutral
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
IMRX

24/7 Wall Street
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
NeutralIMRXMarch 9, 2026
24/7 Wall StreetNeutral
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
IMRX
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy3
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
278M184M92M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-56.0M
Net incomeEarnings
No data available
% positive news of 8 articles
published over the past 14 days
Latest news

Zacks Investment Research
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
NeutralIMRXJuly 15, 2026
Zacks Investment ResearchNeutral
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
IMRX

Zacks Investment Research
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
NeutralIMRXJune 12, 2026
Zacks Investment ResearchNeutral
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
IMRX

Stocktwits
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
NeutralIMRXJune 1, 2026
StocktwitsNeutral
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
IMRX

24/7 Wall Street
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
NeutralIMRXMarch 9, 2026
24/7 Wall StreetNeutral
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
IMRX

Stocktwits
IMRX Stock Closed Over 20% Higher Today: Here’s Why
NeutralIMRXJanuary 8, 2026
StocktwitsNeutral
IMRX Stock Closed Over 20% Higher Today: Here’s Why
IMRX

Zacks Investment Research
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy
NeutralIMRXDecember 29, 2025
Zacks Investment ResearchNeutral
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy
IMRX

Zacks Investment Research
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
NeutralIMRXNovember 10, 2025
Zacks Investment ResearchNeutral
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
IMRX

24/7 Wall Street
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
NeutralIMRXOctober 22, 2022
24/7 Wall StreetNeutral
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
IMRX
About Immuneering Corporation Class A Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees57
CEODr. Benjamin J. Zeskind M.B.A., Ph.D.
IPO DateJul 28, 2021
HeadquartersCambridge, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, CEO & Director | 1983 |
| Mr. Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus | 1946 |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer | 1969 |
| Mr. Michael D. Bookman J.D. | Chief Legal Officer & Secretary | 1987 |
| Mr. Andrew W. Gengos | CFO & Treasurer | 1964 |
| Ms. Paula George CPA | Senior Director of Accounting & Operations and Assistant Corporate Controller | — |
| Ms. Mallory Morales CPA | Senior VP of Finance, Chief Accounting Officer & Assistant Treasurer | 1983 |
| Ms. Jyoti Joshi | Director of Quality Systems & Compliance | — |
| Mr. David Caouette | Vice President of Corporate Communications | — |
| Ms. Leah R. Neufeld | Chief People Officer | 1972 |
Fundamentals
Valuation
Market cap$276.26M
Price-to-sales ratioN/A
Price-to-book value1.47
Price-earnings ratio-4.90
Return on Equity-32.00%
Return on SalesN/A
Return on Assets-30.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.93
Income Statement
Average volume702,950
EBITDA$-53.74M
1 year high (52w)$9.60
1 year low (52w)$3.86
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$16.00
Est return
274.71%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -5.3 | -6.2 | -15.7 | -19.6 | ||||||||
| 2022 | -41.1 | -27.6 | -7.8 | -33.2 | -17.0 | +36.3 | +30.4 | -13.8 | +106.0 | -7.4 | -53.5 | -24.9 |
| 2023 | +4.5 | +17.3 | +90.4 | +18.8 | -25.8 | +7.6 | +4.4 | -15.3 | -14.7 | -0.7 | +1.2 | -11.1 |
| 2024 | -19.8 | +7.8 | -53.0 | -48.4 | -9.2 | -7.2 | -3.4 | -17.8 | +105.8 | -19.8 | +11.8 | +4.8 |
| 2025 | -12.2 | -12.2 | +2.7 | -20.7 | +32.6 | +80.2 | +0.0 | +70.6 | +16.9 | +8.0 | +16.8 | -7.2 |
| 2026 | -30.1 | +3.5 | +5.4 | -1.7 | +7.4 | +10.9 | -18.2 | +19.7 | -12.0 |



